Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

Key Inclusion Criteria:

- The ability to understand and sign a written informed consent form, which must be
obtained prior to initiation of study procedures

- Currently receiving EFV/FTC/TDF FDC for ≥ 6 consecutive months preceding the screening
visit

- Documented plasma HIV-1 RNA levels < 50 copies/mL (or undetectable HIV-1 RNA level
according to the local assay being used if the limit of detection is > 50 copies/mL)
for ≥ 6 months preceding the screening visit. Unconfirmed virologic elevation of ≥ 50
copies/mL after previously reaching viral suppression (transient detectable viremia,
or "blip") and prior to screening is acceptable

- Have no documented resistance to any of the study agents at any time in the past

- HIV-1 RNA < 50 copies/mL at the screening visit

- Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)

- Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin

- Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm^3; platelets
≥50,000/mm^3; hemoglobin ≥ 8.5 g/dL)

- Serum amylase ≤ 5 × ULN (individuals with serum amylase > 5 × ULN will remain eligible
if serum lipase is ≤ 5 × ULN)

- Normal ECG (or if abnormal, determined by the Investigator to be not clinically
significant)

- Adequate renal function: Estimated glomerular filtration rate ≥ 50 mL/min according to
the Cockcroft-Gault formula

Key Exclusion Criteria:

- Hepatitis B surface antigen (HBsAg) positive

- Hepatitis C antibody positive with detectable hepatitis C virus (HCV) RNA (individuals
who have HCV antibody but no detectable HCV RNA are eligible to enroll)

- Individuals experiencing or with a medical history of decompensated cirrhosis (e.g.,
ascites, encephalopathy, etc.)

- Females who are breastfeeding

- Positive serum pregnancy test

- Current alcohol or substance use judged by the Investigator to potentially interfere
with the individual's study compliance

- A history of malignancy within the past 5 years (prior to screening) or ongoing
malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or
resected, non-invasive cutaneous squamous carcinoma. Individuals with cutaneous KS are
eligible, but must not have received any systemic therapy for KS within 30 days of
Baseline/Day 1 and must not be anticipated to require systemic therapy during the
study

- Active, serious infections (other than HIV-1 infection) requiring parenteral
antibiotic or antifungal therapy within 30 days prior to Baseline/Day 1

- Any other clinical condition or prior therapy that, in the opinion of the
Investigator, would make the individual unsuitable for the study or unable to comply
with dosing requirements

- Participation in any other clinical trial (including observational trials) without
prior approval from the sponsor is prohibited while participating in this trial

- Individuals receiving ongoing therapy with any of the following medications in the
table below, including drugs not to be used with FTC, RPV and/or TAF (refer to the
individual agents Prescribing Information); or individuals with any known allergies to
the excipients of FTC/RPV/TAF

Note: Other protocol defined inclusion/exclusion criteria may apply.